TAVO307 / Tavotek - LARVOL DELTA

Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers. (PubMed, Antib Ther) - "A high-affinity anti-CDH17 monoclonal antibody (TAVO307) was generated and conjugated with auristatin-derived cytotoxic payloads to obtain CDH17-directed antibody-drug conjugates (ADCs)...Both CDH17-targeted ADCs and γδ TCEs demonstrated promising potency and efficacy to control GI cancers. They could offer complementary therapeutic options that could be used in combination therapy."

IO biomarker • Journal • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • CDH17 • IL15

TAVO307, a novel ADC targeting CDH17, for the therapy of gastrointestinal cancers (AACR 2025) - "Targeting CDH17 in GI tract cancers, our lead CDH17-MMAE molecule (TAVO307) showed potent tumor cell cytotoxicity in multiple tumor cell lines in cytotoxicity assays as well as in CDX and PDX tumor models. Further preclinical safety assessment, pharmacokinetics and IND-enabling studies are on-going with the goal to develop TAVO307 as the "best-in-class" ADC molecule for the treatment of colon, gastric, pancreatic and oesophagus cancers with significant unmet medical needs. This antibody can also be applied to alternative targeting modalities."

ADC • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17